UroGen Pharma (URGN) investor relations material

Company overview and strategic priorities

• Founded in Israel to address challenges in local cancer treatment with innovative hydrogel technology.

• Focused on launching Zusduri for low-grade intermediate-risk non-muscle invasive bladder cancer.

• Lifecycle management includes expanding UGN-103 and developing UGN-501, plus a recent deal with IntraGel Therapeutics.

Launch performance and physician adoption

• Zusduri revenue grew 73% sequentially to $50.4 million, driven entirely by demand.

• Only 450 of 8,000 target physicians have prescribed so far, with 45% being repeat prescribers.

• Physicians report ease of use and strong patient outcomes, especially in hard-to-treat cases.

• 36-month durability data shows extended recurrence-free periods for patients.

Market dynamics and growth trajectory

• Early adoption was stronger in academic settings due to reimbursement uncertainties; community uptake is now accelerating.

• Community practices accounted for 55% of Q2 business, expected to rise toward 65% at peak.

• Operational improvements are expected as more practices gain experience with the buy-and-bill process.

• Formal guidance on trajectory may be provided after a full year with the permanent J-code, possibly by 2027.